About Us

Avia Vascular is a medical device manufacturer focused on providing more compassionate care with The Ally Device and The Stiletto Device. Through advanced technology, the devices are intended to reduce the need for venipuncture when obtaining blood samples for inpatients and placing extended dwell catheters for those who require frequent infusions. Our primary objective is to provide technology to address the most common, and most invasive procedure to enhance patient experiences, improve outcomes, and reduce cost for providers and hospitals.

Who We Are.

At the core, Avia Vascular is a team of innovators and specialists with a shared desire to solve meaningful problems and improve the quality of healthcare worldwide.  

 Through strategic partnerships and business practices, we are able to leverage business practices to achieve our mission to provide compassionate care, and drive innovation when addressing patient and provider outcomes. We are passionate about our work and dedicated to our mission of developing new technologies exceeding industry expectations.

Our Team

Kevin Cook Avia Vascular CEO

Kevin Cook

CEO

Paul Blackburn Avia

Paul Blackburn, MNA, RN

VP Clinical Development

Nick Corbett Avia

Nick corbett

VP Engineering & Operations

Chad N

Chad Nielson

VP of Quality & Operations

Michael Pell engineering manager blood collection

Michael Pell

Engineering Manager, Blood Collection

Arman Dehlavi manager of engineering

Arman Dehlavi

Manager of Engineering,
Vascular Access

Scott Milligan national account manager

Scott Milligan

National Account Manager

Patrick Eggen RN

Patrick Eggen, RN

Clinical Manager

Diego Piraquive manager of quality

Diego Piraquive

Manager of Quality

Our Investor

Avia Vascular is a subsidiary of MedVenture Health (MVH). MVH partners with entrepreneurs, physicians, and management teams to advance healthcare products, services, and technologies. MVH provides expertise and capital resources to assist in creating value; investing in healthcare companies at a stage in their development where an infusion of capital and strategic assistance will significantly enhance value.